atorvastatin + atorvastatin + atorvastatin

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias

Trial Timeline

Dec 1, 2003 → Oct 1, 2004

NCT ID

NCT00645424

About atorvastatin + atorvastatin + atorvastatin

atorvastatin + atorvastatin + atorvastatin is a approved stage product being developed by Pfizer for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT00645424. Target conditions include Hyperlipidemias.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00645151	Approved	Completed	Apr 1, 2004	Feb 1, 2005	Dyslipidemias
NCT00645424	Approved	Completed	Dec 1, 2003	Oct 1, 2004	Hyperlipidemias
NCT00647543	Approved	Completed	Aug 1, 2003	Apr 1, 2004	Dyslipidemias

Competing Products

5 competing products in Hyperlipidemias

See all competitors

Product	Company	Stage	Hype Score
Evolocumab + Statins (Cardiovascular Agents)	Amgen	Approved	84
SAL003 140 mg + Placebo	Shenzhen Salubris Pharmaceuticals	Phase 3	76
SAL003 140 mg + Placebo	Shenzhen Salubris Pharmaceuticals	Phase 3	76
SLN360 + Placebo	Medpace	Phase 1	30
Bempedoic Acid + Ezetimibe + Placebos	Esperion Therapeutics	Phase 3	72

Other Products from Pfizer